

(19)



Europäisches Patentamt  
European Patent Office  
Office européen des brevets



(11)

**EP 0 974 356 B1**

(12)

**EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention  
of the grant of the patent:  
**24.09.2003 Bulletin 2003/39**

(51) Int Cl.7: **A61K 31/64, A61K 31/155**  
**// (A61K31/64, 31:155,**  
**A61P5:50)**

(21) Application number: **98401781.4**

(22) Date of filing: **15.07.1998**

(54) **Tablets comprising a combination of metformin and glibenclamide**

Tabletten enthaltend eine Kombination von Glibenclamid und Metformin

Comprimés contenant une combinaison de glibenclamide et de metformine

(84) Designated Contracting States:  
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU**  
**MC NL PT SE**  
Designated Extension States:  
**AL LT LV MK RO SI**

• **Nicholson, Geoffrey**  
**Aylesbury, Buckinghamshire HP21 9UT (GB)**

(43) Date of publication of application:  
**26.01.2000 Bulletin 2000/04**

(74) Representative: **Bernasconi, Jean Raymond et al**  
**c/o Cabinet Lavoix,**  
**2, Place d'Estienne d'Orves**  
**75441 Paris Cedex 09 (FR)**

(73) Proprietor: **Merck Sante**  
**69008 Lyon (FR)**

(56) References cited:  
**WO-A-97/17975** **US-A- 4 060 634**

(72) Inventors:  
• **Bonhomme, Yves**  
**69260 Charbonnières les Bains (FR)**

Remarks:

The file contains technical information submitted  
after the application was filed and not included in this  
specification

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

## Description

[0001] The present invention relates to tablets for the treatment of non-insulin dependent diabetes.

[0002] Non-insulin dependent diabetes is a metabolic disorder characterized by hyperglycaemia, which occurs due to insulin deficiency, insulin resistance and reduced glucose tolerance.

[0003] There are two main groups of oral antidiabetic drugs available; these are the sulphonylureas and the biguanidines. Sulphonylureas act by stimulating insulin release and are thus only effective with some residual pancreatic beta-cell activity, examples of sulphonylureas available are glibenclamide, gliclazide, tolbutamide, glipizide, tolazamide, glipizide and chlorpropamide. The biguanidines, such as metformin, act by decreasing gluconeogenesis and by increasing peripheral utilisation of glucose, and as they require endogenous insulin they are only effective with some residual pancreatic islet cell activity.

[0004] The initial treatment of non-insulin dependent diabetes involves diet control and exercise. Only after this has been shown to be inadequate are oral antidiabetic drugs used, and then only to complement the effect of diet and not replace it. Monotherapy with an oral antidiabetic can be an effective treatment for many years. However the efficiency can decrease with time. Due to sulphonylureas and biguanidines having complementary modes of action, combined therapy is now an established form of treatment for non-insulin dependent diabetes.

[0005] As treatment of non-insulin dependent diabetes is control rather than cure patient compliance is critical. Thus to improve patient compliance a combined tablet would be an advantage. The present invention relates to tablets comprising a combination of metformin and glibenclamide. WO 97/17975 discloses a combination of glibenclamide and metformin in a particular ratio which allows to obtain an optimum therapeutical effect.

[0006] It is possible to produce a combination tablet using standard galenic procedures. However, when using standard generic glibenclamide in the combination tablet a reduced bioavailability in comparison to the co-prescribed situation was apparent. It has been found using in-vitro and in-vivo testing that the reduced bioavailability is related to the particle size and the particle size distribution of the glibenclamide. It has been found that particles which are too small result in high glibenclamide blood levels with consequent risk of hypoglycaemia and particles which are too large cannot dissolve sufficiently rapidly from the metformin tablet matrix to give comparable bioavailability with the co-prescribed situation. It is therefore necessary to have a closely defined particle size distribution of the glibenclamide in the combination tablet.

[0007] The selection of a specific size fraction of glibenclamide enables the production of a combination tablet exhibiting comparable glibenclamide bioavailability

to the co-administered tablets, when judged by the area under the curve of the in-vivo analysis.

[0008] The present invention provides a tablet comprising a combination of metformin and glibenclamide, exhibiting a comparable glibenclamide bioavailability to the co-administered tablets.

[0009] The tablet according to the invention contains a combination of glibenclamide and metformin in which the size of the glibenclamide is such that at most 10% of the particles are less than 2  $\mu\text{m}$  and at most 10% of the particles are greater than 60  $\mu\text{m}$ . Preferably, the size of the glibenclamide is such that at most 10% of the particles are less than 3  $\mu\text{m}$  and at most 10% of the particles are greater than 40  $\mu\text{m}$ . This specific particle size range of glibenclamide may be obtained by sieving or air jet milling.

[0010] Metformin may be used as a salt of metformin, such as hydrochloride, fumarate, hydrobromide, p-chlorophenoxy acetate or embonate. The weight ratio of metformin salt to glibenclamide should preferably be between 50/1 to 250/1.

[0011] The tablet according to the present invention may be obtained by a process comprising:

- a) forming granules by wet granulation of a mixture of metformin and glibenclamide;
- b) blending the granules with a tableting aid and diluent, and
- c) tableting the blend thus obtained into tablets.

[0012] Advantageously the mixture used for forming the granules comprises a granulating binder. This granulating binder is in particular a polyvinylpyrrolidone such as for example, a polyvinylpyrrolidone having a molecular weight of 45 000. The polyvinylpyrrolidone may be used in a proportion of 2 to 4% by weight with respect to the final tablet.

[0013] After the granulating step the granules may be sieved and dried.

[0014] The granules are then blended with a diluent and tableting aid. The diluent may be any material usually used for making tablets, such as microcrystalline cellulose. The tableting aid may be any material usually for making tablets, such as magnesium stearate.

[0015] The tablets thus obtained may then be coated with a hydrophilic cellulose polymer and talc. The hydrophilic cellulose polymer may be 2-hydroxypropyl methylcellulose.

[0016] The following examples illustrate the process for the preparation of the tablets.

### Example 1

[0017] A tablet of metformin/metformin/glibenclamide has been prepared as follows:

[0018] 66.6 g of polyvinylpyrrolidone are mixed with 246 g of purified water with a stirrer. 1500 g metformin hydrochloride, 7.5 g of glibenclamide (with a 10 to 90%

size range between 2 to 60  $\mu\text{m}$ ), 42 g croscarmellose sodium and 284.4 g of microcrystalline cellulose are mixed in a granulator. The polyvinylpyrrolidone solution is added to the granulator and the wet mass is granulated. The granules are extruded through a 1 mm mesh. The granules are emptied into a preheated fluidised bed dryer and the granules are dried. 97.5 g of microcrystalline cellulose is mixed into the granules using a tumbling mixer. 12 g of magnesium stearate is added to the tumbling mixer and mix. The granule mix is tableted using a suitable tablet press. The tablets are coated with a 2% hydroxypropyl methylcellulose coat in a coating machine.

### Example 2

[0019] A tablet of metformin/glibenclamide has been prepared as follows:

[0020] 5.83 g of glibenclamide (with a 10 to 90% size range between 2 to 60  $\mu\text{m}$ ), are preblended with 32.67 g of croscarmellose sodium. 46.67 g of polyvinylpyrrolidone are mixed with 93.33 g of purified water with a stirrer. The glibenclamide-croscarmellose sodium blend is mixed with 1166.6 g of metformin hydrochloride in a granulator. The polyvinylpyrrolidone solution is added to the granulator and the wet mass is granulated. The granules are emptied into a preheated fluidised bed dryer and the granules are dried. The particle size of the granules is reduced by passing through a 1 mm mesh. 131.83 g of microcrystalline cellulose are mixed into the granules in the granulator. 16.3 g of magnesium stearate are added to the granulator and mixed. The granule mix is tableted using a suitable tablet press. The tablets are coated with a 2% hydroxypropyl methylcellulose coat in a coating machine.

[0021] In-vivo bioavailability tests were performed with tablets prepared as disclosed in example 2, using two batches of glibenclamide. The two batches have the following 10 to 90% particle size range:

batch A: 3.47-38.08  $\mu\text{m}$

batch B: 15.63-91.6  $\mu\text{m}$ .

[0022] The distribution of the particle size of batches A and B are illustrated in figure 1.

[0023] The two batches of tablets were administered to healthy patients in comparison to co-administered glibenclamide (marketed under the trade name Daonil) and metformin hydrochloride (16 patients for each group).

[0024] The comparative concentrations of glibenclamide in a tablet comprising a combination of metformin and respectively the batch A and the batch B of glibenclamide and with the co-administration are shown respectively in figures 2 and 3.

[0025] The area under the curve (AUC) are the following:

	AUC (ng/ml/h)
combination with batch A	790.5
combination with batch B	353.0
co-administration	869.3

It appears that with the combination according to the invention with batch A the AUC is substantially the same as in the case of co-administration, whereas with the combination with batch B the AUC is more clearly different.

### 15 Claims

1. A tablet comprising a combination of metformin and glibenclamide in which the size of the glibenclamide is such that at most 10% of the particles are less than 2  $\mu\text{m}$  and at most 10% of the particles are greater than 60  $\mu\text{m}$ .
2. A tablet as claimed in claim 1 in which the size of the glibenclamide is such that at most 10% of the particles are less than 3  $\mu\text{m}$  at most 10% of the particles are greater than 40  $\mu\text{m}$ .
3. A tablet as claimed in claim 1 or 2 in which metformin is present as metformin salt and the weight ratio of metformin salt to glibenclamide is 50/1 to 250/1.
4. A tablet as claimed in anyone of claims 1 to 3 which is obtained by a process comprising:
  - a) forming granules by wet granulation of a mixture of metformin and glibenclamide;
  - b) blending the granules with a tableting aid
  - c) tableting the blend thus obtained into tablets.

### Patentansprüche

1. Eine Tablette, enthaltend eine Kombination von Metformin und Glibenclamid, in der die Größe des Glibenclamids derart ist, daß höchstens 10% der Teilchen kleiner als 2  $\mu\text{m}$  und höchstens 10% der Teilchen größer als 60  $\mu\text{m}$  sind.
2. Eine Tablette nach Anspruch 1, in der die Größe des Glibenclamids derart ist, daß höchstens 10% der Teilchen kleiner als 3  $\mu\text{m}$  und höchstens 10% der Teilchen größer als 40  $\mu\text{m}$  sind.
3. Eine Tablette nach Anspruch 1 oder 2, in der Metformin als Metforminsalz vorliegt und das Gewichtsverhältnis Metforminsalz zu Glibenclamid 50/1 zu 250/1 beträgt.

4. Eine Tablette nach einem der Ansprüche 1 bis 3, die durch ein Verfahren erhalten wird, das die folgenden Verfahrensstufen umfaßt:

a) Erzeugen eines Granulats durch Naßgranulierung eines Gemischs aus Metformin und Glibenclamid; 5

b) Mischen des Granulats mit Tablettierhilfsstoffen und 10

c) Tablettieren des so erhaltenen Gemischs zu Tabletten.

15

#### Revendications

1. Comprimé comprenant une association de metformine et de glibenclamide, dans lequel la taille du glibenclamide est telle qu'au plus 10 % des particules sont plus petites que 2  $\mu\text{m}$  et qu'au plus 10 % des particules sont plus grosses que 60  $\mu\text{m}$ . 20

2. Comprimé selon la revendication 1, dans lequel la taille du glibenclamide est telle qu'au plus 10 % des particules sont plus petites que 3  $\mu\text{m}$  et qu'au plus 10 % des particules sont plus grosses que 40  $\mu\text{m}$ . 25

3. Comprimé selon la revendication 1 ou 2, dans lequel la metformine est présente sous forme d'un sel de metformine, et le rapport pondéral du sel de metformine au glibenclamide est de 50/1 à 250/1. 30

4. Comprimé selon l'une quelconque des revendications 1 à 3, obtenu selon un procédé comprenant: 35

a) une formation de granulés par granulation en milieu humide d'un mélange de metformine et de glibenclamide;


b) un mélange des granulés avec un adjuvant de formation de comprimé; 40

c) une formation en comprimés du mélange ainsi obtenu.


45

50


55



**FIG. 1**



**FIG. 2**



**FIG. 3**

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☒ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**